Search Results | Blood | American Society of Hematology

1-20 of 56

2 3

Sort by

Sort Order Select

Journal Articles

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases

Monica S. Thakar, Larisa Broglie, Brent Logan, Andrew Artz, Nancy Bunin, Lauri M. Burroughs, Caitrin Fretham, David A. Jacobsohn, Alison W. Loren, Joanne Kurtzberg, Caridad A. Martinez, Shin Mineishi, Adam S. Nelson, Ann Woolfrey, Marcelo C. Pasquini, Mohamed L. Sorror

Blood (2019) 133 (7): 754–762.

DOI: https://doi.org/10.1182/blood-2018-09-876284

Published: 2019

Includes: Supplemental data

Journal Articles

The Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Transplantation

Claudio G Brunstein, MD PhD, Marcelo C. Pasquini, MDMS, Soyoung Kim, Mingwei Fei, MS, Andrew Artz, MD, Minoo Battiwalla, MD, Nelli Bejanyan, MD, Robert Peter Gale, MD ScD, PhD, Peiman Hematti, MD, Oscar Boutros Lahoud, MD, Marcos De Lima, MD, Ran Reshef, MD, Seth J Rotz, MD, Bipin N. Savani, MD, Harry C. Schouten, MD, Shin Mineishi, MD, John Rogosheske, PharmD, Miguel-Angel Perales, MD

Blood (2017) 130 (Supplement 1): 3292.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3292.3292

Published: 2017

Journal Articles

Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Hongtao Liu, MD PhD, Andrew Artz, MD, Richard A. Larson, MD, Satyajit Kosuri, MD, Wendy Stock, MD, Michael R. Bishop, MD

Blood (2017) 130 (Supplement 1): 3312.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3312.3312

Published: 2017

Journal Articles

Fludarabine Melphalan Conditioning Followed By T-Replete Haplo Identical (Haplo) Transplantation or Haplo Cord (HC) Transplantation

Koen Van Besien, MD PhD, Andrew Artz, MD, Richard E Champlin, MD, Danielle Guarneri, Michael R. Bishop, MD, Julianne Chen, Tsiporah B. Shore, MD, Hongtao Liu, MD PhD, Gabriela Rondon, MD, Sebastian A. Mayer, MD, Stefan O. Ciurea

Blood (2017) 130 (Supplement 1): 3328.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3328.3328

Published: 2017

Journal Articles

Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Is Feasible and Results in Higher Donor Chimerism, Faster Immune Re-Constitution and Prolonged PFS

Kothari Shawn, MD, Andrew Artz, MD, Sang Mee Lee, PhD, Noreen Fulton, BS, Jae-Hyun Park, Wendy Stock, MD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Justin Kline, MD, Lucy Godley, MD PhD, James LaBelle, MD PhD, Satyajit Kosuri, MD, Peter A Riedell, MD, Yusuke Nakamura, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2017) 130 (Supplement 1): 4572.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4572.4572

Published: 2017

Journal Articles

Validation of Pre-Transplant Biomarker Measurement and Risk Score for Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant (HCT)

Michael J. Leukam, MD, Lucy Godley, MD PhD, Justin Kline, MD, Richard A. Larson, MD, Hongtao Liu, MD PhD, Olatoyosi Odenike, MD, Wendy Stock, MD, Michael R. Bishop, MD, Andrew Artz, MD

Blood (2017) 130 (Supplement 1): 4558.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4558.4558

Published: 2017

Journal Articles

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Blood (2017) 130 (9): 1156–1164.

DOI: https://doi.org/10.1182/blood-2017-03-772368

Published: 2017

Includes: Supplemental data

Journal Articles

Comorbidity from Solid Tumor or Hematologic Malignancy Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) May Both Increase Non-Relapse Mortality

Christopher Robert D'Angelo, MD, Brianna Novitsky, BA, Sang Mee Lee, PhD, Lucy A Godley, MD PhD, Justin Kline, MD, Richard A. Larson, MD, Hongtao Liu, MD PhD, Olatoyosi Odenike, MD, Wendy Stock, MD, Michael R. Bishop, MD, Andrew Artz, MD

Blood (2016) 128 (22): 5844.

DOI: https://doi.org/10.1182/blood.V128.22.5844.5844

Published: 2016

Journal Articles

Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children

Andrew C. Harris, MD, Jaap Jan Boelens, MDPhD, Kwang Woo Ahn, PhD, Mingwei Fei, MS, Allistair Abraham, MD, Andrew Artz, MD, Christopher C. Dvorak, MD, Haydar Frangoul, MD, Cesar O Freytes, MD, Robert Peter Gale, MD PhD, Sanghee Hong, MD, Hillard M. Lazarus, MD, Shin Mineishi, MD, Taiga Nishihori, MD, Tracey O'Brien, MD, Kirsten M. Williams, MD, Marcelo C. Pasquini, MD, John E Levine, MD MS

Blood (2016) 128 (22): 664.

DOI: https://doi.org/10.1182/blood.V128.22.664.664

Published: 2016

Journal Articles

Stratification of Allogeneic Hematopoietic Cell Transplant By Risk of Developing Veno-Occlusive Disease: A Model for Assigning a Risk Score

Christopher Strouse, MD, Ying Zhang, Mei-Jie Zhang, PhD, Alyssa DiGilio, MS, Marcelo C. Pasquini, MD, Mary M. Horowitz, MD MS, Stephanie J. Lee, MD, Muthalagu Ramanathan, MD, Wichai Chinratanalab, MD, Alison W Loren, MD MS, Linda J. Burns, MD, Andrew Artz, MD, Kathleen F. Villa, MS, Wael Saber, MD MS

Blood (2016) 128 (22): 983.

DOI: https://doi.org/10.1182/blood.V128.22.983.983

Published: 2016

Journal Articles

Excellent Clinical Outcome for Relapsed and Refractory Lymphoma Patients with Haplo-Cord Allogeneic Stem Cell Transplantation

Jingmei Hsu, MD PhD, Andrew Artz, MD MS, Sebastian A. Mayer, MD, Michael R. Bishop, MD, Adrienne A. Phillips, MD MPH, Sonali M. Smith, MD, Usama Gergis, MD, Justin Kline, MD, Tsiporah B. Shore, MD, Koen van Besien, MD

Blood (2016) 128 (22): 3496.

DOI: https://doi.org/10.1182/blood.V128.22.3496.3496

Published: 2016

Journal Articles

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

Blood (2016) 128 (22): 505.

DOI: https://doi.org/10.1182/blood.V128.22.505.505

Published: 2016

Journal Articles

Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 679.

DOI: https://doi.org/10.1182/blood.V128.22.679.679

Published: 2016

Journal Articles

Combined Treatment with Lenalidomide (LEN) and Epoetin Alfa (EA) Is Superior to Lenalidomide Alone in Patients with Erythropoietin (Epo)-Refractory, Lower Risk (LR) Non-Deletion 5q [Del(5q)] Myelodysplastic Syndrome (MDS): Results of the E2905 Intergroup Study-an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Alan F List, MD, Zhuoxin Sun, PhD, Amit Verma, MD, John M. Bennett, MD, Kathy L McGraw, PhD, Lisa Ann Nardelli, BS, Jaroslaw P Maciejewski, MD PhD FACP, Jessica K Altman, MD, Puneet Cheema, MD, David F. Claxton, MD, Rami S. Komrokji, MD, Selina Luger, MD, Ryan Mattison, MD, Tim Wassenaar, MD, Andrew Artz, MD, Charles A Schiffer, MD, Martin S. Tallman, MD

Blood (2016) 128 (22): 223.

DOI: https://doi.org/10.1182/blood.V128.22.223.223

Published: 2016

Journal Articles

Combination of Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) Is Feasible and Tolerable

Amy Y Wang, MD, Howie Lawrence Weiner, Margaret Green, Richard A. Larson, MD, Olatoyosi Odenike, MD, Andrew Artz, MD, Lucy A Godley, MD, PhD, Michael J. Thirman, MD, Jane E Churpek, MD, Emily K. Curran, MD, Kristen Pettit, MD, Wendy Stock, MD, Hongtao Liu, MDPhD

Blood (2016) 128 (22): 212.

DOI: https://doi.org/10.1182/blood.V128.22.212.212

Published: 2016

Journal Articles

Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy

Katarzyna Rojek, BS, Eric Nickels, Barbara Niestadt, Rafael Marquez, Amittha Wickrema, PhD, Andrew Artz, MD MS, Koen van Besien, MD, Ming K Lee, Jeremy P. Segal, MD PhD, Mary-Claire King, Tom Walsh, Akiko Shimamura, MD PhD, Sioban Keel, MD, Jane E Churpek, MD, Lucy A Godley, MD PhD

Blood (2015) 126 (23): 3163.

DOI: https://doi.org/10.1182/blood.V126.23.3163.3163

Published: 2015

Journal Articles

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies

Yi-Bin Chen, MD, Jennifer Le-Rademacher, PhD, Deidre Marie Kiefer, MPH, Mehdi Hamadani, MD, John F. DiPersio, MD PhD, Mark R Litzow, MD, Michael Craig, MD, Mitchell E. Horwitz, MD, Andrew Artz, MD MS, Brian McClune, DO, Edmund K Waller, MD PhD, Hugo F. Fernandez, MD, Hien Kim Duong, MD, Hati Kobusingye, Mandi Proue, MPH, Rebecca J. Drexler, MPH, Mary M. Horowitz, MD MS, John P. Miller, MD PhD, Steven M. Devine, MD

Blood (2015) 126 (23): 389.

DOI: https://doi.org/10.1182/blood.V126.23.389.389

Published: 2015

Journal Articles

Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML)

Yasmin H Karimi, MD, Nitin Jain, MD, Margaret Green, Lucy A Godley, MD, PhD, Howie Lawrence Weiner, Gregory Malnassy, Noreen Fulton, Andrew Artz, MD MS, Hongtao Liu, MDPhD, Michael J. Thirman, MD, Michael Daunov, Richard A. Larson, MD, Wendy Stock, MD, Olatoyosi Odenike, MD

Blood (2015) 126 (23): 3777.

DOI: https://doi.org/10.1182/blood.V126.23.3777.3777

Published: 2015

Journal Articles

The Effect of IV Iron Therapy on HIF Pathway and HIF Regulated Genes in Elderly Patients with Unexplained Anemia

Levon Katsakhyan, BS, Sabina Swierczek, PhD, Andrew Artz, MD MS, Elizabeth A Price, MD MPH, Stanley L. Schrier, MD, Harvey Jay Cohen, MD, Josef T. Prchal, MD, Victor R. Gordeuk, MD

Blood (2015) 126 (23): 4533.

DOI: https://doi.org/10.1182/blood.V126.23.4533.4533

Published: 2015

Journal Articles

Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML)

Andrew Hantel, MD, Niloufer Khan, MD, Richard A. Larson, MD, Lucy A. Godley, MD PhD, Michael J. Thirman, MD, Andrew Artz, MD MS, Olatoyosi Odenike, MD, Hongtao Liu, MDPhD, Jane E. Churpek, MD, Darren King, MD, Elizabeth Rich, MD, Kwang Jin Choi, MD, Randall W. Knoebel, PharmD, BCOP, Wendy Stock, MD

Blood (2015) 126 (23): 2518.

DOI: https://doi.org/10.1182/blood.V126.23.2518.2518

Published: 2015

2 3

NARROW

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases

The Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Transplantation

Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Fludarabine Melphalan Conditioning Followed By T-Replete Haplo Identical (Haplo) Transplantation or Haplo Cord (HC) Transplantation

Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Is Feasible and Results in Higher Donor Chimerism, Faster Immune Re-Constitution and Prolonged PFS

Validation of Pre-Transplant Biomarker Measurement and Risk Score for Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant (HCT)

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Comorbidity from Solid Tumor or Hematologic Malignancy Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) May Both Increase Non-Relapse Mortality

Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children

Stratification of Allogeneic Hematopoietic Cell Transplant By Risk of Developing Veno-Occlusive Disease: A Model for Assigning a Risk Score

Excellent Clinical Outcome for Relapsed and Refractory Lymphoma Patients with Haplo-Cord Allogeneic Stem Cell Transplantation

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia

Combination of Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) Is Feasible and Tolerable

Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies

Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML)

The Effect of IV Iron Therapy on HIF Pathway and HIF Regulated Genes in Elderly Patients with Unexplained Anemia

Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only